Charles River Laboratories (CRL): Invesco Ltd. amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Invesco Ltd. filed an amended Schedule 13G with the SEC (accession 0000914208-26-000392) updating its beneficial ownership stake in Charles River Laboratories (CRL). The filing is a passive-investor disclosure rather than a signal of activist intent, and the headline did not specify a change in share count or percentage. Because 13G amendments are routine for large asset managers, the update matters mainly for tracking institutional positioning in the contract research organization. Investors will watch for the filing's detailed ownership figures and any subsequent 13F or 13G/A disclosures for confirmation of Invesco's current position.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Charles River Laboratories (CRL), Invesco Ltd.
A linked name opens that asset's sentiment page.